National Center for Complementary and Integrative Health (NCCIH) — Biomedical Watch V2

Traitements7programmes

Essais4liés

Publications13liées

SourceDBlocale

Traitements

7

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
NaproxenThis pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain. The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen). Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit. The study includes several experimental pain tests. These include: a heat and capsaicin skin test that causes short-term skin sensitivity, a UVB light test that causes a temporary sunburn-like sensitivity, and a cold pressor test, in which a hand is placed in very cold water for a short time. Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done. Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks. This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....	Maladie coronarienne	Non applicable	Immunomodulation + Traitement symptomatique	United States	À vérifier
Patient-Centered Assessment of Symptoms and OutcomesBackground: The cause of fatigue is not well understood. It can be felt differently by different people. Some people think there are different types of fatigue, with different causes. Researchers think a therapy to treat one type of fatigue in one condition should be able to treat that type of fatigue in other conditions. Objective: To understand the types of fatigue. Eligibility: Adults 18 and older who have felt fatigue for more than a month, and non-fatigued adults Design: Participants will be screened with a physical exam, their medical history, a vision test, and blood and urine tests. Participants will begin to track the foods they eat. This study will involve up to 10 visits. Each visit will last no more than 4 hours. In Stage 1, participants will have an interview, fill out questionnaires, and play computer games. They will take walking and handgrip tests. They will give blood, urine, and saliva samples. They will wear a wrist monitor at home for 7 days and write down their activities. They will be put into a group: fatigue or non-fatigued control. In Stage 2, participants will answer questionnaires and give a blood sample. They will have heart tests. They may take exercise and lung function tests that include wearing a nose clip. They may have an optional brain MRI: They may wear an electrode cap on their head during the scan to measure brain activity. They will lie on table that slides into a cylinder. They may perform tasks in the scanner. After the study, participants might be contacted about other studies.	Myopathies	À vérifier	Traitement symptomatique	United States	À vérifier
pregabalinApproximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.	Épilepsie, Maladie coronarienne, SEP	Non applicable	À vérifier	United States	À vérifier
pregabalinApproximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.	Épilepsie	Phase 3	À vérifier	United States, Argentina, Bosnia and Herzegovina, Bulgaria, Czechia, Germany, Hong Kong, Hungary, India, Malaysia, Mexico, Poland, Puerto Rico, Romania, Russia, Serbia, Singapore, Thailand	À vérifier
pregabalinApproximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs. The present study will compare the efficacy of two different dosages of pregabalin CR dosed once daily as compared to placebo, when used as adjunctive therapy in subjects requiring adjunctive therapy for partial onset epilepsy, using a randomized, parallel group design.	Épilepsie	Phase 3	À vérifier	United States, Canada	À vérifier
Patient-Centered Assessment of Symptoms and OutcomesBackground: The cause of fatigue is not well understood. It can be felt differently by different people. Some people think there are different types of fatigue, with different causes. Researchers think a therapy to treat one type of fatigue in one condition should be able to treat that type of fatigue in other conditions. Objective: To understand the types of fatigue. Eligibility: Adults 18 and older who have felt fatigue for more than a month, and non-fatigued adults Design: Participants will be screened with a physical exam, their medical history, a vision test, and blood and urine tests. Participants will begin to track the foods they eat. This study will involve up to 10 visits. Each visit will last no more than 4 hours. In Stage 1, participants will have an interview, fill out questionnaires, and play computer games. They will take walking and handgrip tests. They will give blood, urine, and saliva samples. They will wear a wrist monitor at home for 7 days and write down their activities. They will be put into a group: fatigue or non-fatigued control. In Stage 2, participants will answer questionnaires and give a blood sample. They will have heart tests. They may take exercise and lung function tests that include wearing a nose clip. They may have an optional brain MRI: They may wear an electrode cap on their head during the scan to measure brain activity. They will lie on table that slides into a cylinder. They may perform tasks in the scanner. After the study, participants might be contacted about other studies.	Myopathies	À vérifier	Traitement symptomatique	United States	À vérifier
NaproxenThis pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain. The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen). Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit. The study includes several experimental pain tests. These include: a heat and capsaicin skin test that causes short-term skin sensitivity, a UVB light test that causes a temporary sunburn-like sensitivity, and a cold pressor test, in which a hand is placed in very cold water for a short time. Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done. Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks. This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....	Maladie coronarienne	Non applicable	Immunomodulation + Traitement symptomatique	United States	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Naproxen	Maladie coronarienne	Non applicable	NCT07549490	Human Experimental Models of Pain (HEMP)	NOT_YET_RECRUITING
Patient-Centered Assessment of Symptoms and Outcomes	Myopathies	À vérifier	NCT03952624	Patient-Centered Assessment of Symptoms and Outcomes	ACTIVE_NOT_RECRUITING
pregabalin	Épilepsie	Phase 3	NCT00141388	To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures	COMPLETED
pregabalin	Épilepsie	Phase 3	NCT01262677	Once-A-Day Pregabalin For Partial Seizures	COMPLETED

Publications

13

Molécule	Indication / population	Titre	Journal	Date
pregabalin		Prescribing Patterns of Gabapentinoids in Patients with Chronic Obstructive Pulmonary Disorder.	COPD
pregabalin		Gabapentinoids and unexplained death in general practice: Case series and feasibility study arising from a critical incident.	The European journal of general practice
pregabalin		Association Between the Use of Gabapentinoids and Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis.	Current therapeutic research, clinical and experimental
Patient-Centered Assessment of Symptoms and Outcomes		Palliative care among cancer patients in Georgia: System-level gaps identified through health-related quality of life discrepancies.	Journal of public health research
Patient-Centered Assessment of Symptoms and Outcomes		Depressive Symptoms Are Associated With Lower Patient Expectations for Recovery Following Cardiac Intensive Care Unit Admission.	The Journal of cardiovascular nursing
pregabalin		An NLRP3 inflammasome inhibitor evoked dose-dependent anti-allodynia in the hindpaws of a rat model of chemotherapy-induced peripheral neuropathy.	Inflammopharmacology
pregabalin		Comparative Effectiveness, Safety, and Costs of Gabapentinoids in Older Adults With Long-Term Opioid Use.	Journal of the American Geriatrics Society
pregabalin		Vitamin B12 and pregabalin combination restored brain waves dynamics and behavior in chronic unpredictable mild stress (CUMS) model of depression.	Naunyn-Schmiedeberg's archives of pharmacology
pregabalin		Comparison of Ketamine and Pregabalin on Postoperative Opioid Usage and Pain Management in Spinal Fusion: Systematic Review and Network Meta-analysis.	Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
pregabalin		The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.	Inflammopharmacology
pregabalin		Once-Nightly Pregabalin for Co-Occurring Nightmares, Poor Sleep, and Headaches: A Case Series.	Nature and science of sleep
pregabalin		Management of Pain and Pruritus in Pediatric Recessive Dystrophic Epidermolysis Bullosa.	Clinical case reports
pregabalin		Pharmacological and non-pharmacological therapies for chronic pancreatitis pain: a narrative review.	Frontiers in physiology